<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000642130"><TermName>ridaforolimus</TermName><TermPronunciation>(rih-duh-foh-ROH-lih-mus)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of soft tissue and bone cancers. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus stops cells from dividing and may cause cancer cells to die. It is a type of mTOR inhibitor.  Also called AP23573.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000704183" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;ridaforolimus&quot;" language="en" id="_3"/><MediaLink ref="CDR0000704182" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;ridaforolimus&quot;" language="es" id="_4"/><SpanishTermName>ridaforolimus</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de los cánceres del tejido blando y del hueso. También está en estudio para el tratamiento de otros tumores sólidos y el cáncer de la sangre. El deforolimus impide que las células se multipliquen y podría destruir las células cancerosas. Es un tipo de inhibidor mTOR. También se llama AP23573.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-07-31</DateFirstPublished><DateLastModified>2009-07-21</DateLastModified></GlossaryTerm>
